-
公开(公告)号：US10792282B2
公开(公告)日：2020-10-06
申请号：US15918929
申请日：2018-03-12
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Rajinder Singh , Matthew Duncton , Jing Zhang , Salvador Alvarez , Kin Tso , Sacha Holland , Rose Yen , Rao Kolluri , Thilo Heckrodt , Yan Chen , Esteban Masuda , Hui Li , Donald G. Payan
IPC: A61K31/506 , C07D471/04 , C07D498/04
Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
-
公开(公告)号：US10709703B2
公开(公告)日：2020-07-14
申请号：US16691352
申请日：2019-11-21
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Rajinder Singh , Ankush Argade , Donald Payan , Susan Molineaux , Sacha J. Holland , Jeffrey Clough , Holger Keim , Somasekhar Bhamidipati , Catherine Sylvain , Hui Li , Alexander B. Rossi
IPC: A61K31/505 , A61K31/519 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D239/48 , C07D417/14 , A61K31/506 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/551 , A61K45/06 , C07D498/04 , C07D265/36 , A61K31/5395 , C07D495/04 , C07F5/02 , C07D498/14 , C07D407/14
Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
-
公开(公告)号：US20200216431A1
公开(公告)日：2020-07-09
申请号：US16733571
申请日：2020-01-03
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Yan Chen , Vanessa Taylor , Hui Li , Rajinder Singh
IPC: C07D413/12 , C07D451/02 , A61K31/635 , A61K31/5415 , C07F9/6558 , C07D498/04 , C07D487/10 , C07D471/04 , C07D413/14 , A61K31/675 , A61K31/55 , A61K31/538 , C07D491/08 , C07D487/04 , C07D471/08 , C07D419/14 , A61K45/06 , A61K31/551 , A61K31/541 , A61K31/54 , A61K31/5383 , A61K31/5377 , A61K31/506 , C07D487/08 , C07D413/04 , C07D403/12 , C07D401/14 , A61K31/155
Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
-
公开(公告)号：US20200181130A1
公开(公告)日：2020-06-11
申请号：US16551393
申请日：2019-08-26
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Hui Li , sambaiah Thota , David Carroll , Ankush Argade , Kin Tso , Arvinder Sran , Jeffrey Clough , Holger Keim , Somasekhar Bhamidipati , Vanessa Taylor , Robin Cooper , Rajinder Singh , Brian Wong
IPC: C07D413/12 , C07F7/08 , C07D417/12 , C07D401/14 , A61K45/06 , C07F7/10 , C07D498/04 , A61K39/395 , A61K38/13 , A61K31/695 , A61K31/541 , A61K31/5383 , A61K31/538 , A61K31/5377 , A61K31/506 , A61K31/505 , A61K31/436 , A61K31/343 , C07D239/48 , C07D413/14 , C07D403/12 , C07D401/12 , C07D239/42 , C07D403/04
Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.
-
公开(公告)号：US10556891B2
公开(公告)日：2020-02-11
申请号：US15988920
申请日：2018-05-24
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Yan Chen , Vanessa Taylor , Hui Li , Rajinder Singh
IPC: A61K31/506 , C07D413/12 , A61K31/155 , C07D401/14 , C07D403/12 , C07D413/04 , C07D487/08 , A61K31/5377 , A61K31/5383 , A61K31/54 , A61K31/541 , A61K31/551 , A61K45/06 , C07D419/14 , C07D471/08 , C07D487/04 , C07D491/08 , A61K31/538 , A61K31/55 , A61K31/675 , C07D413/14 , C07D471/04 , C07D487/10 , C07D498/04 , C07F9/6558 , A61K31/5415 , A61K31/635 , C07D451/02
Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
-
Patent Agency Ranking
公开(公告)号：US10421752B2
公开(公告)日：2019-09-24
申请号：US15637833
申请日：2017-06-29
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Hui Li , Sambaiah Thota , David Carroll , Ankush Argade , Kin Tso , Arvinder Sran , Jeffrey Clough , Holger Keim , Somasekhar Bhamidipati , Vanessa Taylor , Robin Cooper , Rajinder Singh , Brian Wong
IPC: A61K31/506 , C07D413/12 , C07D403/04 , C07D239/42 , C07D239/48 , C07D401/12 , C07D403/12 , C07D413/14 , A61K31/343 , A61K31/436 , A61K31/505 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/541 , A61K31/695 , A61K38/13 , A61K39/395 , C07D498/04 , C07F7/10 , A61K45/06 , C07D401/14 , C07D417/12 , C07F7/08 , C07D285/22
Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.
-
公开(公告)号：US10369148B2
公开(公告)日：2019-08-06
申请号：US15366931
申请日：2016-12-01
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Rajinder Singh , Ankush Argade , Donald G. Payan , Susan Molineaux , Sacha J. Holland , Jeffrey Clough , Holger Keim , Somasekhar Bhamidipati , Catherine Sylvain , Hui Li , Alexander B. Rossi
IPC: A61K31/505 , A61K31/519 , C07D239/48 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , A61K31/506 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/551 , A61K45/06 , C07D498/04 , C07D265/36 , A61K31/5395 , C07D495/04 , C07F5/02 , C07D498/14 , C07D407/14
Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
-
公开(公告)号：US20170151239A1
公开(公告)日：2017-06-01
申请号：US15205725
申请日：2016-07-08
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Rajinder Singh , Ankush Argade , Donald Payan , Susan Molineaux , Sacha Holland , Jeffrey Clough , Holger Keim , Somasekhar Bhamidipati , Catherine Sylvain , Hui Li , Alexander Rossi
IPC: A61K31/505 , A61K31/538 , A61K31/5383 , A61K31/506
CPC classification number: A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/5395 , A61K31/551 , A61K45/06 , C07D239/48 , C07D265/36 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D407/14 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D495/04 , C07D498/04 , C07D498/14 , C07F5/027
Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
-
公开(公告)号：US20170137411A1
公开(公告)日：2017-05-18
申请号：US15419660
申请日：2017-01-30
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Yan Chen , Vanessa Taylor , Hui Li , Rajinder Singh
IPC: C07D413/12 , C07D471/08 , C07D403/12 , A61K31/635 , A61K31/5377 , C07F9/6558 , A61K31/675 , C07D487/08 , A61K31/551 , C07D471/04 , C07D413/14 , A61K31/541 , C07D401/14 , C07D491/08 , C07D487/04 , C07D451/02 , C07D487/10 , C07D419/14 , A61K31/5415 , A61K31/55 , C07D498/04 , A61K31/538 , A61K31/5383 , A61K31/506
CPC classification number: C07D413/12 , A61K31/155 , A61K31/506 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/54 , A61K31/541 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/635 , A61K31/675 , A61K45/06 , C07D401/14 , C07D403/12 , C07D413/04 , C07D413/14 , C07D419/14 , C07D451/02 , C07D471/04 , C07D471/08 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/08 , C07D498/04 , C07F9/65583
Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
-
公开(公告)号：US09566283B2
公开(公告)日：2017-02-14
申请号：US14793506
申请日：2015-07-07
Applicant: Rigel Pharmaceuticals, Inc.
Inventor： Yan Chen , Vanessa Taylor , Hui Li , Rajinder Singh
IPC: A01N43/54 , A61K31/505 , A61K31/5415 , A61K31/155 , C07D401/14 , C07D403/12 , C07D413/04 , C07D487/08 , A61K31/506 , A61K31/5377 , A61K31/5383 , A61K31/54 , A61K31/541 , A61K31/551 , A61K45/06 , C07D413/12 , C07D419/14 , C07D471/08 , C07D487/04 , C07D491/08 , A61K31/538 , A61K31/55 , A61K31/675 , C07D413/14 , C07D471/04 , C07D487/10 , C07D498/04 , C07F9/6558
CPC classification number: C07D413/12 , A61K31/155 , A61K31/506 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/54 , A61K31/541 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/635 , A61K31/675 , A61K45/06 , C07D401/14 , C07D403/12 , C07D413/04 , C07D413/14 , C07D419/14 , C07D451/02 , C07D471/04 , C07D471/08 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/08 , C07D498/04 , C07F9/65583
Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
Abstract translation: 公开了式I化合物，含有它们的组合物，以及用于化合物和组合物用于治疗JAK途径的调节或JAK激酶，特别是JAK 2和JAK 3的抑制在治疗上有用的条件的方法。
-
-
-
-
-
-
-
-
-
Search Results
115
records
(took 0.072 seconds)
